ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

セフジニル

Cefdinir

HCID 6915944
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
91832-40-5
標準SMILES
C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\O)c3csc(N)n3)[C@H]2SC1
InChIKey
RTXOFQZKPXMALH-GHXIOONMSA-N
分子式
C14H13N5O5S2
平均分子量
395.4 g/mol
単同位体質量
395.03581088

概要

Cefdinir is a cephalosporin compound having 7beta-2-(2-amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino- and 3-vinyl side groups. It has a role as an antibacterial drug. It is a cephalosporin and a ketoxime.

名称と識別子

優先名称
Cefdinir
IUPAC
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
現地名
セフジニル
英語名
Cefdinir
分子式
C14H13N5O5S2
分子量
395.41

名称と別名

cefdinir91832-40-5OmnicefCefzonCefdinirumCFDNFK 482FK-482CI-983Cefdinir anhydrousDTXSID8046084BMY-28488
名称をさらに表示
セフロジール(6R)-7α-[[(Z)-2-(2-アミノ-4-チアゾリル)-2-(ヒドロキシイミノ)アセチル]アミノ]-3-エテニル-8-オキソ-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-2-カルボン酸セフゾン(6R,7R)-7α-[[(2-アミノ-4-チアゾリル)[(Z)-ヒドロキシイミノ]アセチル]アミノ]-3-エテニル-8-オキソ-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-2-カルボン酸(6R,7R)-3-ビニル-7-[(2-アミノ-4-チアゾリル)[(Z)-ヒドロキシイミノ]アセチルアミノ]-8-オキソ-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-2-カルボン酸セフジニル(6R,7R)-7-[(2-アミノ-4-チアゾリル)[(Z)-ヒドロキシイミノ]アセチルアミノ]-8-オキソ-3-ビニル-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-2-カルボン酸[6R,7R,(-)]-7-[(2-アミノ-4-チアゾリル)[(Z)-ヒドロキシイミノ]アセチルアミノ]-8-オキソ-3-ビニル-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-2-カルボン酸セフジニル (JP17)セフニール(6R,7R)-7-[(2Z)-2-(2-アミノ-1,3-チアゾール-4-イル)-2-(N-ヒドロキシイミノ)アセトアミド]-3-エテニル-8-オキソ-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-2-カルボン酸シオジニルsyn-7-[2-(2-amino-4-thiazolyl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid7-[2-(2-AMINOTHIAZOL-4-YL)-2-HYDROXYIMINOACETYLAMINO]-8-OXO-3-VINYL-5-THIA-1-AZA-BICYCLO[4.2.0]OCT-2

物性

構造計算による物性補完中

XLogP
0
極性表面積
212 Ų
水素結合供与体数
4
水素結合受容体数
10
回転可能結合数
5
重原子数
26
形式電荷
0
複雑度
739

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Antibiotics

LogP-0.2
Solubility8.78e-02 g/L
Human Drugs · 3 件

Breast Feeding; Lactation; Anti-Infective Agents; Antibacterial Agents; Cephalosporins;

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point>135
Physical DescriptionSolid
Dissociation Constants · 2 件

3.35

9.7

物理化学的性質

融点
180 °C · >180°C dec.
比重(密度)
1.89 · 1.89±0.1 g/cm3(Predicted)
貯蔵温度
2 · Keep in dark place,Sealed in dry,2-8°C
溶解性
希塩酸: わずかに溶ける

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H315 (20%): Causes skin irritation [Warning Skin corrosion/irritation]

P233, P260, P261, P264, P264+P265, P271, P272, P280, P284, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P403, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 5 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesSkin Irrit. 2 (20%)

毒性情報

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Cefdinir

vLess-DILI-concern

7

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
EPA Human Health Benchmarks for Pharmaceuticals · 6 件

Cefdinir

14.0

59.2

The total daily dose for all infections is 600 mg.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 600 mg/day, Lowest Therapeutic Dose (LTD): 7.5 mg/kg-day, and Screening Dose: 0.003 mg/kg-day.

12-Nov-21

安全データ

wgk
3
rtecs
XI0367250

化学と産業

薬理情報

ATC Code · 2 件

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

Protein BindingThe plasma protein binding of cefdinir ranges from 60% to approximately 70%.
Pharmacodynamics · 1 件

Cefdinir is a bactericidal agent that treats bacterial infections by interfering with cell wall synthesis. Cefdinir exerts broad-spectrum activity against a variety of gram-positive and gram-negative bacterial infections. It is effective against several beta-lactamase enzyme producing bacteria. As a result, many organisms that are resistant to other cephalosporins may be susceptible to cefdinir.

Mechanism of Action · 1 件

Five-member thiazolidine rings that make up penicillins are replaced in cephalosporins by a six-member dihydrothiazine ring, conferring greater bactericidal activity. This 6-member ring enables cefdinir and other cephalosporins to resist inactivation by certain bacterial enzymes. With a mechanism similar to other beta-lactam antibiotics, the bactericidal activity of cefdinir is caused by the inhibition of cell wall synthesis via binding to penicillin-binding proteins (PBPs). Cefdinir, like other cephalosporins, penetrates the bacterial cell wall, combats inactivation by beta-lactamase enzymes, and inactivates penicillin-binding proteins. This interferes with the final step of transpeptidation in cell walls, eventually leading to cell lysis, which eventually leads to the death of bacteria that are susceptible to this drug. Cefdinir has shown affinity to penicillin protein binding proteins 2 and 3. It has also been shown to inhibit transpeptidase enzymes of various bacteria, which may play a role in its bactericidal action. One in vitro study suggests that cefdinir inhibits myeloperoxidase release extracellularly. The impact of this potential drug target in relation to its mechanism of action is unknown.

Biological Half-LifeThe average plasma elimination half-life is about 1.7 hours in adults. In children and healthy infants, plasma elimination half-life ranges from 1.2–1.5 hours.
Metabolism/Metabolites

関連反応

6 件
反応記録を作成
HRID 18693 の反応式
HRID 18693生成物として
HRID 898083 の反応式
HRID 898083反応物として
HRID 969252 の反応式
HRID 969252反応物として
HRID 1296225 の反応式
HRID 1296225生成物として
HRID 1296226 の反応式
HRID 1296226生成物として
HRID 2213706 の反応式
HRID 2213706生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
(6R,7R)-3-Vinyl-7-[(2-amino-4-thiazolyl)[(Z)-hydroxyimino]acetylamino]-8-oxo-5-thia-1-azabicyclo[4.2.0]octa-2-ene-2-carboxylic acid
8-[2-(2-amino-1,3-thiazol-4-yl)-1-hydroxy-2-nitroso-ethenyl]amino-4-ethenyl-7-oxo-2-thia-6-azabicyclo[4.2.0]oct-4-ene-5-carboxylicacid
(6R,7R)-7α-[[(2-Amino-4-thiazolyl)[(Z)-hydroxyimino]acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-[[(2Z)-(2-Amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo--5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
[6R-[6α,7β(Z)]]_7-[[(2-Amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyimino-acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CI0FAO63WCPD-134393NSC-758926CHEBI:3485CI983FK482DTXCID20820060(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(N-hydroxyimino)acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

データベース識別子

CAS
91832-40-5
PubChem CID
6915944
DTXSID
DTXSID8046084
ChEMBL
CHEMBL927
ChEBI
CHEBI:3485
UNII
CI0FAO63WC
EC Number
643-088-1
Nikkaji
J227.563E
酸解離定数(Pka)
9.7 · 9.70(at 25℃)
外見
個体
色
淡黄色~淡黄色
水溶解度
水に溶ける
Merck
14 · 14,1920
BCS Class
4 · 4
主な用途
医薬品
InChIKey
RTXOFQZKPXMALH-GHXIOONMSA-N
SMILES
N12[C@@]([H])([C@H](NC(/C(/C3=CSC(N)=N3)=N\O)=O)C1=O)SCC(C=C)=C2C(O)=O
CAS データベース
91832 · 91832-40-5(CAS DataBase Reference)

化学的性質

化学的特性Pale Yellow Solid

毒性
LD50 orl-rat: >5600 mg/kg IYKEDH 23,93,1992
hs_code
2941906000
ストレージクラス
11 - Combustible Solids
This drug is not significantly metabolized and its pharmacological actions are mainly attributed to the parent drug.
FDA Pharmacological Classification · 6 件

CI0FAO63WC

CEFDINIR

Established Pharmacologic Class [EPC] - Cephalosporin Antibacterial

Chemical Structure [CS] - Cephalosporins

Cefdinir is a Cephalosporin Antibacterial.

CEFDINIR

MeSH Pharmacological Classification · 1 件

Agents that are structurally similar to other CEPHALOSPORINS but have a broader spectrum of activity against bacteria than the first and second generation cephalosporins. These agents cover more resistant STREPTOCOCCUS, STAPHYLOCOCCUS, gram-positive anaerobes, and more resistant strains of HAEMOPHILUS, NEISSERIA, PROTEUS, ESCHERICHIA COLI, and KLEBSIELLA (HNPEK).

Absorption, Distribution and Excretion · 4 件

Maximal plasma cefdinir concentration can be attained between 2-4 hours after an ingested dose. The bioavailability of cefdinir depends on the formulation used. The estimated bioavailability of cefdinir in the capsule form is approximately 16%-21%, depending on the dose. Absolute bioavailability after the administration of a suspension of cefdinir is 25%.. The Cmax of cefdinir is 1.60 μg/mL after a 300 mg dose with an AUC of 7.05. Cmax is 2.87 μg/mL after a 600 mg dose with an AUC of 11. A meal high in fat can reduce the absorption of cefdinir by up to 15%, however, this is not a cause for clinically significant changes, therefore cefdinir may be taken with or without food. When given with aluminum or magnesium-containing antacids or iron, cefdinir absorption may decrease. It is recommended to allow 2 hours between cefdinir administration and the administration of these agents.

This drug is mainly excreted by the kidneys. Dose adjustments may be required for patients with renal impairment or patients on dialysis. Approximately 18.4% of a 300 mg dose of cefdinir was found unchanged in the urine after a 300 mg dose was administered during a pharmacokinetic study of 21 individuals. A large proportion of the administered dose is excreted in the feces, although the majority is found in the urine.

The average volume of distribution of cefdinir in adults is about 0.35 L/kg and 0.67 L/kg in children. Another resource estimates the volume of distribution in adults at 1.56–2.09 L/kg. Cefdinir is found to be distributed in various tissues at clinically effective concentrations. It may be found in the epithelial lining fluid, bronchial mucosa, tonsils, sinuses, skin blister fluid, as well as the middle ear fluid. Third-generation cephalosporins such as cefdinir cross the blood-brain barrier and are found in high concentrations in the cerebrospinal fluid, unlike their first and second generation counterparts. The wide tissue distribution of cefdinir allows it to treat a variety of infections throughout the body.

The renal clearance in healthy adults in a pharmacokinetic study was 2.0 (± 1.0) mL/min/kg and the clearance in patients with renal failure was lower, decreasing in proportion to the degree of renal impairment. Dose adjustment is required in patients with renal impairment.

Cellular LocationsCytoplasm

用途と製造

UsesUse (kg) in USA (2002): 11300
応用分野 · 3 件

用途第 3 世代のセファロスポリン 系抗生物質です。ペニシリン結合タンパクに 結合し、細胞壁の合成阻害作用を示します。 抗菌スペクトルは広く、グラム陰性菌に対し、 強い抗菌力を示します。

説明Cefdinir is an orally active, beta-lactamase stable cephalosporin with a broad spectrum of activity. Compared to other oral cephalosporins, cefdinir is more potent against Gram-positive bacteria, especially Staphylococci. Its activity against Gram-negative bacteria such as E.coli,K. pneumoniae and P.mirabilis is similar to cefixime, but superior to cefaclor and cephalexin.

使用A Cephalosporin antibiotic structurally similar to Cefixime

上流・下流製品情報

上流原料

Amine compound臭化アセチルアニソールトリフルオロ酢酸(トリフェニルホスホラニリデン)アセトアルデヒド酢酸エチルN-トリメチルシリルアセトアミドN,N-ジメチルアセトアミドクロロメタン亜硝酸ナトリウムS-2-Benzothiazolyl (Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyimino thioacetate(Z)-2-(2-アミノチアゾル-4イル)2トリチロキシイミノチオ酢酸 ベンゾチアゾル エステル7アミノ-3ビニル-3セフェム-4カルボン酸

補足説明

定義ChEBI: A cephalosporin compound having 7beta-2-(2-amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino- and 3-vinyl side groups.